prikaz prve stranice dokumenta Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
  Preuzmi
PDF 2.6 MB
Znanstveni rad - Izvorni znanstveni rad
Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
Frontiers in Neurology, 10 (2019); https://doi.org/10.3389/fneur.2019.00253
Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; Seze, Jérôme de; Cruz, Dionisio Dela; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; Wijmeersch, Bart Van Više autora...

Citirajte ovaj rad

Barclay, K., Carruthers, R., Traboulsee, A., Bass, A. D., LaGanke, C., Bertolotto, A. ... Wijmeersch, B. V. (2019). Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology, 10.. doi: 10.3389/fneur.2019.00253

Barclay, Krista, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology, vol. 10, 2019. https://doi.org/10.3389/fneur.2019.00253

Barclay, Krista, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, et al. "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings." Frontiers in Neurology 10 (2019). https://doi.org/10.3389/fneur.2019.00253

Barclay, K., et al. (2019) 'Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings', Frontiers in Neurology, 10. doi: 10.3389/fneur.2019.00253

Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, i sur.. Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings. Frontiers in Neurology [Internet]. 22.03.2019. [pristupljeno 16.04.2024.];10. doi: 10.3389/fneur.2019.00253

K. Barclay, et al., "Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings", Frontiers in Neurology, vol. 10, Ožujak 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:548907. [Citirano: 16.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:548907
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Best practices for long-term monitoring and follow-up of Alemtuzumab-Treated MS patients in real-world clinical settings
AutorKrista Barclay
AutorRobert Carruthers
AutorAnthony Traboulsee
AutorAnn D. Bass
AutorChristopher LaGanke
AutorAntonio Bertolotto
AutorAaron Boster
AutorElisabeth G. Celius
AutorJérôme de Seze
AutorDionisio Dela Cruz
AutorMario Habek
AutorJong-Mi Lee
AutorVolker Limmroth
AutorSven G. Meuth
AutorCelia Oreja-Guevara
AutorPatricia Pagnotta
AutorCindy Vos
AutorTjalf Ziemssen
AutorDarren P. Baker
AutorBart Van Wijmeersch
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5 consecutive days at baseline, and 3 consecutive days 12 months later), resulted in significantly greater improvements in clinical and MRI outcomes vs. subcutaneous interferon beta-1a over 2 years in patients with active relapsing-remitting MS (RRMS) who were either treatment-naive (CARE-MS I; NCT00530348) or had an inadequate response to prior therapy (CARE-MS II; NCT00548405). Efficacy with alemtuzumab was maintained over 7 years in subsequent extension studies (NCT00930553; NCT02255656), in the absence of continuous treatment and with a consistent safety profile. There is an increased incidence of autoimmune events in patients treated with alemtuzumab (mainly thyroid events, but also immune thrombocytopenia and nephropathy), which imparts a need for mandatory safety monitoring for 4 years following the last treatment. The risk management strategy for alemtuzumab-treated patients includes laboratory monitoring and a comprehensive patient education and support program that enables early detection and effective management of autoimmune events, yielding optimal outcomes for MS patients. Here we provide an overview of tools and techniques that have been implemented in real-world clinical settings to reduce the burden of monitoring for both patients and healthcare providers, including customized educational materials, the use of social media, and interactive online databases for managing healthcare data. Many practices are also enhancing patient outreach efforts through coordination with specialized nursing services and ancillary caregivers. The best practice recommendations for safety monitoring described in this article, based on experiences in real-world clinical settings, may enable early detection and management of autoimmune events, and help with implementation of monitoring requirements while maximizing the benefits of alemtuzumab treatment for MS patients.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Neurology
Brojčani podacivol. 10
p-ISSN1664-2295
DOIhttps://doi.org/10.3389/fneur.2019.00253
URN:NBNurn:nbn:hr:105:548907
Datum objave publikacije2019-03-22
URL dokumentahttp://doi.org/10.3389/fneur.2019.00253
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:23:51